- Home
- LVLU vs VTVT Comparison
LVLU vs VTVT Comparison
Compare LVLU & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- VTVT
- Stock Information
- Founded
- LVLU 1996
- VTVT 2015
- Country
- LVLU United States
- VTVT United States
- Employees
- LVLU N/A
- VTVT N/A
- Industry
- LVLU Catalog/Specialty Distribution
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- VTVT Health Care
- Exchange
- LVLU Nasdaq
- VTVT Nasdaq
- Market Cap
- LVLU 47.5M
- VTVT 38.8M
- IPO Year
- LVLU 2021
- VTVT 2015
- Fundamental
- Price
- LVLU $0.89
- VTVT $13.48
- Analyst Decision
- LVLU Hold
- VTVT Strong Buy
- Analyst Count
- LVLU 3
- VTVT 1
- Target Price
- LVLU $1.58
- VTVT $35.00
- AVG Volume (30 Days)
- LVLU 36.4K
- VTVT 8.3K
- Earning Date
- LVLU 03-05-2025
- VTVT 03-12-2025
- Dividend Yield
- LVLU N/A
- VTVT N/A
- EPS Growth
- LVLU N/A
- VTVT N/A
- EPS
- LVLU N/A
- VTVT N/A
- Revenue
- LVLU $324,699,000.00
- VTVT $1,000,000.00
- Revenue This Year
- LVLU N/A
- VTVT N/A
- Revenue Next Year
- LVLU $1.72
- VTVT N/A
- P/E Ratio
- LVLU N/A
- VTVT N/A
- Revenue Growth
- LVLU N/A
- VTVT 11011.11
- 52 Week Low
- LVLU $0.89
- VTVT $7.38
- 52 Week High
- LVLU $2.13
- VTVT $30.99
- Technical
- Relative Strength Index (RSI)
- LVLU 31.13
- VTVT 41.82
- Support Level
- LVLU $0.92
- VTVT $13.46
- Resistance Level
- LVLU $1.03
- VTVT $14.35
- Average True Range (ATR)
- LVLU 0.08
- VTVT 0.53
- MACD
- LVLU -0.01
- VTVT 0.01
- Stochastic Oscillator
- LVLU 0.00
- VTVT 13.58
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.